ASPE — Aspen Neuroscience, Inc.
ASPE dilution and offerings
- Last offering: 424B4 (Oct 2026)
$14.89
Last close: · regular session
After-hours $14.72 -1.14% ·
Recent offering filing (424B4, Oct 2026). Latest SEC filing: 3 on Oct 30, 2026. ASPE closed at $14.89 on Oct 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ASPE in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Pharmaceutical Preparations
- Country: US
- Exchange: NASDAQ
- Website: https://www.aspenneuroscience.com
Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.
Latest SEC filings for ASPE
Latest ASPE news
- Bispecific biotech Bambusa and Parkinson’s-focused Aspen slide on trading debuts Read article
- Aspen Neuroscience prices IPO at $15 per share Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.